HWM
YMAB

HighMark Wealth Management’s Y-mAbs Therapeutics YMAB Stock Holding History

HighMark Wealth Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-220
Closed -$2.66K – 620
2024
Q2 		$2.66K Hold
220
– – ﹤0.01% 448
2024
Q1 		$3.58K Hold
220
– – ﹤0.01% 402
2023
Q4 		$1.5K Hold
220
– – ﹤0.01% 486
2023
Q3 		$1.2K Hold
220
– – ﹤0.01% 490
2023
Q2 		$1.49K Hold
220
– – ﹤0.01% 479
2023
Q1 		$1.1K Hold
220
– – ﹤0.01% 535
2022
Q4 		$1.07K Sell
220
-500
-69% -$3.63K ﹤0.01% 470
2022
Q3 		$10K Hold
720
– – 0.01% 253
2022
Q2 		$11K Hold
720
– – 0.01% 239
2022
Q1 		$9K Sell
720
-150
-17% -$1.54K 0.01% 291
2021
Q4 		$14K Sell
870
-233
-21% -$4.98K 0.01% 219
2021
Q3 		$31K Sell
1,103
-178
-14% -$5.61K 0.02% 147
2021
Q2 		$43K Buy
1,281
+930
+265% +$29.9K 0.03% 129
2021
Q1 		$11K Sell
351
-30
-8% -$1.23K 0.01% 227
2020
Q4 		$19K Sell
381
-1,899
-83% -$87.8K 0.02% 167
2020
Q3 		$88K Buy
2,280
+2,041
+854% +$81.2K 0.08% 69
2020
Q2 		$10K Buy
+239
New +$9.04K 0.01% 205

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

HighMark Wealth Management's YMAB Position: Q3 2024 in Review

HighMark Wealth Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2024, closing a stake of 220 shares — an estimated $2.66K sold.

HighMark Wealth Management first reported a position in YMAB in Q2 2020 and held it in 17 quarters. The position peaked at $88K in Q3 2020. 105 funds tracked by Wall St. Rank hold YMAB as of Q3 2024.

  • HighMark Wealth Management reported no remaining Y-mAbs Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HighMark Wealth Management sold 220 Y-mAbs Therapeutics shares in Q3 2024, an estimated $2.66K.
  • HighMark Wealth Management first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 17 quarters.
  • HighMark Wealth Management's Y-mAbs Therapeutics position peaked at $88K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2024.

Based on HighMark Wealth Management's 13F filing for Q3 2024, filed 17 Oct 2024.